InVivo Therapeutics Holdings Valuation
| NVIVDelisted Stock | USD 1.38 0.07 5.34% |
Today, the firm appears to be overvalued. InVivo Therapeutics retains a regular Real Value of $1.15 per share. The prevalent price of the firm is $1.38. Our model calculates the value of InVivo Therapeutics from evaluating the firm fundamentals such as return on equity of -0.98, and Return On Asset of -0.54 as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that InVivo Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of InVivo Therapeutics is based on 3 months time horizon. Increasing InVivo Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the InVivo stock is determined by what a typical buyer is willing to pay for full or partial control of InVivo Therapeutics Holdings. Since InVivo Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of InVivo Stock. However, InVivo Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.38 | Real 1.15 | Hype 1.38 | Naive 1.41 |
The intrinsic value of InVivo Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence InVivo Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of InVivo Therapeutics Holdings helps investors to forecast how InVivo stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of InVivo Therapeutics more accurately as focusing exclusively on InVivo Therapeutics' fundamentals will not take into account other important factors: InVivo Therapeutics Total Value Analysis
InVivo Therapeutics Holdings is now forecasted to have valuation of (7.59 M) with market capitalization of 995.92 K, debt of 949 K, and cash on hands of 13.03 M. The negative valuation of InVivo Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the InVivo Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(7.59 M) | 995.92 K | 949 K | 13.03 M |
InVivo Therapeutics Asset Utilization
One of the ways to look at asset utilization of InVivo is to check how much profit was generated for every dollar of assets it reports. InVivo Therapeutics retains a negative application of resources of -0.54 (percent), losing $0.005371 for each dollar of resources held by the firm. Ineffective asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of InVivo Therapeutics Holdings shows how unsuccessful it operates for each dollar spent on its resources.InVivo Therapeutics Ownership Allocation
Roughly 96.54 (percent) of InVivo Therapeutics outstanding shares are held by general public with 0.02 % owned by insiders and only 3.44 pct. by outside corporations.InVivo Therapeutics Profitability Analysis
Net Loss for the year was (9.33 M) with profit before overhead, payroll, taxes, and interest of 0.About InVivo Therapeutics Valuation
Our relative valuation model uses a comparative analysis of InVivo Therapeutics. We calculate exposure to InVivo Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of InVivo Therapeutics's related companies.InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries . The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. Invivo Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 7 people.
InVivo Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as InVivo Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 1.5 M |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in InVivo Stock
If you are still planning to invest in InVivo Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the InVivo Therapeutics' history and understand the potential risks before investing.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |